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Background: A prospective study was performed to compare the prevalence of morphometric vertebral fractures
(MVF) between patients with inflammatory bowel disease (IBD) and healthy subjects and to identify predictive
factors of fracture.
Methods: A total of 107 patients with IBD (53 with Crohn’s disease and 54 with ulcerative colitis) and 51 healthy
subjects participated in the study. Information about anthropometric parameters, toxins, previous fractures, and
parameters related to this disease were evaluated. The index of vertebral deformity, bone mass density (BMD), and
biochemical parameters were calculated.
Results: A total of 72 fractures were detected in 38.32% of patients with IBD, and 10 fractures were detected in
13.73% of healthy subjects; the risk of fracture in patients with IBD was higher than that in control subjects (OR,
4.03; 95% CI, 1.652–9.847; p< 0.002). We found no correlation between fracture and BMD in patients with IBD
(lumbar spine, r =−0.103, p= 0.17 and femoral neck, r =−0.138, p= 0.07). Corticosteroid treatment was not
associated with prevalent vertebral fractures nor with taking corticosteroids (r = 0.135, p= 0.14) or the duration for
which they were taken (r = 0.08, p= 0.38), whereas this relationship was present in the controls (r =−0.365, p= 0.01).
In the multivariate analysis, none of the measured parameters were significantly predictive of fracture, only to
manifested IBD. Hypovitaminosis D was observed in 55.14% of patients with IBD.
Conclusions: The prevalence of morphometric vertebral fractures is higher in patients with IBD than in the healthy
population, without association with BMD or corticoid treatment. Simply having IBD was proven to be a predictive
factor of fracture. We observed a high incidence of hypovitaminosis D in patients with IBD.
Keywords: Morphometric vertebral fractures, Inflammatory bowel disease, Bone mineral density, Bone remodelingBackground
Inflammatory bowel disease (IBD) has been associated
with low bone mass and a high prevalence of osteopenia
and densitometric osteoporosis [1-4]. The etiopathogen-
esis and risk factors leading to this complication remain
controversial [5-7]. An increased risk of developing an
osteoporotic fracture because of low bone mass is
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reproduction in any medium, provided the orOsteoporosis is associated with a high risk of spinal
fracture. Clinical problems of vertebral fractures include
severe and chronic back pain, height loss, spinal deform-
ity, and disability. New vertebral fractures are associated
with substantial increases in back pain and increasing
functional limitations, even those that are not recog-
nized clinically, and are predictive of additional fractures.
Vertebral fractures may represent a serious lifelong
handicap among younger patients [8].
Data regarding the prevalence and risk of fracture in
patients with IBD are currently scarce; thus, clinical rele-
vance in the context of this disease remains to be clarified.
Studies assessing the risk of fracture in IBD are scarce
and controversial and use different methodologies [8-12],l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the appearance of these fractures are much more limited.
Most are focused on patients with Crohn’s disease
(CD) [8-11] and evaluate the prevalence of fractures in
patients with low bone mass, which introduces an
important bias [8]. Other studies evaluate the prevalence
of vertebral crush fractures only in the IBD group with-
out quantifying these fractures in a control group with
similar characteristics [8-12].
We found no publications studying the prevalence of
morphometric vertebral crush fractures in patients with
IBD who were consecutively included during 1 year in a
specialized unit and compared with a control group of
subjects with similar ages and anthropometric character-
istics during the same period of time. Thus, we under-
took this experiment to prove that there is a higher
prevalence of fractures in patients with IBD than in
healthy subjects.
The primary aim of the study was to evaluate the
prevalence of morphometric vertebral crush fractures in
patients with IBD and to compare it with the prevalence
in a control population with similar characteristics. As a
secondary goal, we aimed to identify differences in bio-
chemical parameters and bone mineral density (BMD)
between the two groups to detect possible predictive
factors of fracture in patients with IBD.
Methods
Patients
This was a case–control study of 107 patients with IBD
(median age, 36.0 years; range, 22-67 years). Of the 107
patients, 53 were diagnosed with CD and 54 were diag-
nosed with ulcerative colitis (UC) after endoscopy and
biopsy. The control group included 51 healthy subjects
with a median age of 36.0 years (range, 22-69 years).
CD/UC/healthy ratio was 1/1/1.
Patients were recruited during 1 year in an IBD mono-
graphic unit from the Digestive Diseases Unit of the
University “Hospital Virgen Macarena” (Seville). Inclu-
sion criteria were as follows: age between 22 and 70 years,
diagnosis of IBD after endoscopy and bowel biopsy, and
acquisition of informed consent. Exclusion criteria were
as follows: suffering from any disease involved in bone
metabolism; previous or current treatment related to bone
metabolism (calcitonin, bisphosphonates, parathormone
(PTH), calcium, vitamin D, anabolic steroids, androgens,
hormone replacement therapy, fluor therapy) and second-
ary osteoporosis (rheumatoid arthritis or renal, hepatic,
or endocrine disease).
Controls were randomly chosen from the blood bank
donors of the HUV Macarena. They were matched by
sex and age with IBD patients after ruling out pathology
that alters bone metabolism. The same exclusion criteria
were followed.Data compiled from all participants included age (years)
at the time of inclusion, gender, weight (kg), height (cm),
body mass index (BMI), age at menopause, menstrual
record, contraceptive use, calcium intake (null, moderate,
or high), exposure to toxins such as alcohol (null, moder-
ate, or high) and tobacco (null, <20 cigarettes/day, or
>20 cigarettes/day), previous vertebral crush fracture,
and intense or frequent back pain. In patients with IBD,
age at the beginning of the disease, years of evolution,
type of disease (CD or UC), corticoid treatment and
duration (more or less than 1 year), bowel resection, and
lactose intolerance (by the hydrogen breath test) were also
included.
All participants provided written informed consent,
and the study was approved by the ethics committee of
this hospital.
Measurement of dorsal and lumbar spinal X-rays
To establish the prevalence of vertebral crush fractures,
posteroanterior and lateral X-rays of the dorsal and lum-
bar spine were performed in all participants, including
the area from T4 to L4. On the lateral view, six points
were considered on each vertebra to determine the
anterior, middle, and posterior height of the analyzed
vertebrae. The assessment for the presence of morpho-
metric fractures was performed in a blinded fashion by
two independent observers who did not know whether
the radiograph was of a case or control subject. They
used the semi-quantitative method (Genant’s classification
[13,14] as modified by Black) [15]. A morphometric verte-
bral fracture was considered when a decrease of at least
20% was observed in any height measurement; compared
with the others, this was a difference of >4 mm. Deform-
ities and fractures due to nonosteoporotic causes (trauma
or degenerative deformities) were not considered.
Bone mineral density measurement
We measured bone mineral density (BMD) by dual
energy X-ray absorptiometry (QDR-1000 Hologic den-
sitometer; Waltham, MA, USA) of the lumbar spine
(L2–L4) and proximal right femur. Results are expressed
in absolute values (gHA/cm2). According to the WHO
recommendations for postmenopausal women, BMD
was defined as normal with a T-score of>−1 SD, osteo-
penia as a T-score of<−1 and>−2.5 SD, and osteopor-
osis as a T-score of<−2.5.
Biochemical parameters
Blood samples were taken at baseline to determine the
following serum values: calcium (mg/dl), phosphorus
(mg/dl), alkaline phosphatase (U/dl), osteocalcin (ng/
ml), C-reactive protein (CRP) (mg/dl), parathormone
(PTH) (pg/ml), 25-hydroxycholecalciferol (25-OH-D3)
(ng/ml), serum osteoprotegerin (OPG) (pg/ml), and
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levels (pg/ml).
Calcium, phosphorus, CRP, and alkaline phosphatase
were determined by standard methods (self-analyzers).
Osteocalcin was measured using a commercial radio-
immunoassay (RIA) kit (Metra Biosystems, Inc., CA,
USA). The intra-assay variability (intra-assay coefficient
of variation, IA-CV) was <3%, and the inter-assay vari-
ability (IE-CV) was <2.1%.
Intact PTH was determined by RIA (Allegro Anti-
body; Nichols Institute, San Juan Capistrano, CA, USA)
(normal range, 10–65 pg/ml). The IE-CV was <3.6%,
and the IA-CV was <1.2%.
Determinations of 25-OH-D3 were performed by RIA
(Incstar Corporation, Stillwater, MN, USA) (normal
range, 9–45 ng/ml). The IA-CV was 4.5%, and the IE-CV
was 4.9%.
Serum OPG and RANKL levels were quantified by
enzyme-linked immunosorbent assay (ELISA; Inmun-
diagnostik Bensheim and Biomedica, Austria). The detec-
tion limit was 0.14 pmol/l for OPG, and the IA-CV was
4%; for RANKL, the detection limit was 0.08 pmol/l, and
the IA-CV was 4%.
Samples were stored at −80°C until measurement to
avoid interassay variability.
Statistical analysis
Quantitative variables were expressed as mean and
standard deviations. Qualitative variables were compared
using the chi-square test. For normal distributions,
Student’s t test was applied. For variables without normal
distributions, the Mann–Whitney U test was applied.
Normality was verified using the Kolmogorov–Smirnov
test. Correlation between variables was determined using
Pearson’s correlation coefficient for normal variables and
Spearman’s coefficient for variables without a normal
distribution. Bivariate analysis was applied to calculate
the predictive values of each variable. Analysis was
statistically significant when p< 0.05 and the level of
confidence was 95%. Beta error was set at 20%. SPSS
17.0 for Windows (SPSS, Inc., Chicago, IL, USA) was
used for data analysis.
Results
We analyzed data from 107 patients with IBD (average
age, 37.4 ± 10.4 years); 53 were diagnosed with CD
and 54 were diagnosed with UC after endoscopy and
biopsy; 64.5% were men and 35.5% were women. In the
group of women, 23.7% were menopausal (mean age,
50.5 ± 11.0 years). In the control group, we analyzed 51
healthy subjects with an average age of 39.3 ± 11.0 years,
including 43.1% men and 56.9% women. Of women in
the control group, 27.5% were menopausal (mean age,
52.1 ± 9.1 years).Disease onset was earlier in patients with CD than in
those with UC (median, 25.9 ± 9.2 vs. 31.5 ± 9.8 years).
Of the 53 patients with CD, 74.5% were diagnosed
between 17 and 40 years of age (A2 of the Montreal
classification), and 25.45% were diagnosed after age 40
(A3 of the Montreal classification). None were diagnosed
at <22 years of age.
In terms of disease location, 26.82% had involvement
of the terminal ileum (L1 of the Montreal classification),
34.16% had involvement of the colon (L2 of the Montreal
classification), and 39.02% had involvement of the ileo-
colon (L3 of the Montreal classification). No patient had
isolated involvement of the upper gastrointestinal tract
(L4 of the Montreal classification).
In terms of the clinical pattern, 68.29% of patients had
a nonstricturing and nonpenetrating pattern (B1 of the
Montreal classification), 7.31% had a stricturing pattern
(B2 of the Montreal classification), and 24.39% had a
penetrating pattern (B3 of the Montreal classification).
The B3/B3p ratio was 2.0.
Of the 54 patients with UC, according Montreal classi-
fication of the extent of UC, 34.78% had ulcerative proc-
titis (E1), 26.08% had involvement in the distal colon
(E2), and 39.13% had pancolitis (E3). No patient had
short bowel syndrome.
The extension and location of the inflammatory process
had no significant influence on BMD or vertebral frac-
tures in patients with CD nor in patients with UC.
No significant differences were observed in any of
the anthropometric parameters studied between the
two groups.
Vertebral crush fractures
In our study, the prevalence of morphometric vertebral
crush fractures was higher in patients with IBD than in
controls of the same age and gender.
Forty-one patients with IBD (44.5%; average age,
36.7 ± 9.8 years) had a history of one or more fractures;
26 were men (average age, 38.92 ± 10.5 years), and 15
were women (average age, 33.0 ± 7.4 years). In this
group, 72 fractures were finally reported. In these
patients, vertebral deformities were grade I (68.29%) and
II (31.7%) according to Genant’s classification. In the
control group, seven patients suffered fractures (13.7%);
five were men (average age, 54.0 ± 11.1 years) and two
were women (average age, 51.0 ± 9.8 years). The total
number of fractures was 10. In this group, vertebral
deformities were grade I (57.14%), II (28.57%), or III
(14.28%).
The proportion of patients with fractures was identical
in patients with CD or UC (39.6% vs. 38.8%), although it
was higher in both than in the control group (p< 0.0001).
Moreover, vertebral crush fractures occurred earlier in
IBD patients as seen by the difference in age (IBD,
Table 2 BMD in control group with or without fractures
BMD spine BMD femoral
neck
Controls fractured (7) 0.859 ± 0.18 0.713 ± 0.9
Controls non fractured (44) 1.030 ± 0.15 0.873 ± 0.9
p 0.004 0.007
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p=0.004).
Fractures were more frequent in men than in women
in the IBD and control groups, although differences were
not statistically significant.
Bone mass was not directly related to fractures in the
IBD group: differences in BMD were not found between
patients with or without fractures in either the lumbar
spine or the femur. Notably, most patients with fractures
had a normal bone mass (40.5%); 35.7% were osteopenic,
and 21.4% manifested osteoporosis.
We found no correlation between fractures and BMD.
Control group subjects with vertebral crush fractures,
however, were older than those without fractures
(53.1 ± 10.0 vs. 37.1 ± 9.5; p= 0.005) in both the lumbar
spine and femur. Bone mass was significantly lower in
patients with fractures (Tables 1 and 2). In the fracture
control group, 42.8% of patients had normal bone mass
and 57.1% had osteopenia. A statistically significant
negative correlation was observed between fractures and
BMD in both the lumbar spine (r =−0.365; p= 0.01) and
femur (r =−0.30; p= 0.02) in this group.
Age and fracture were not related in the IBD group, in
which 65.8% of patients with fractures were <40 years
old, and a higher incidence of fracture was noted be-
tween 22 and 39 years of age. On the contrary, frac-
tures in the control group were not present before
43 years of age.
Menopause in women with IBD did not determine the
appearance of fractures or differences in bone mass or
biochemical parameters between patients with IBD and
control subjects.
A correlation between fracture and corticosteroid
treatment was not observed. When analyzing cortico-
steroid treatment in fracture patients with IBD, 14.63%
did not require corticosteroids, 65.85% were treated for
<1 year, and 19.51% were continuously treated for peri-
ods of >1 year. In patients with fractures, 22% had never
required corticosteroids, 50% were treated sporadically
for <1 year, and 28% were treated for >1 year.
In both the IBD and control groups, the fractures were
located between D5 and L4; 47% were located between
D7 and D9.
Back pain was not associated with fracture in either
patients with IBD or healthy subjects (IBD, r = 0.066,
p= 0.53; healthy group, r =−0.117, p= 0.41). A highTable 1 BMD in IBD patients with or without fractures
BMD spine BMD femoral
neck
Patients fractured (41) 0.937 ± 0.19 0.776 ± 0.17
Patients non fractured (66) 0.938 ± 0.12 0.793 ± 0.11
p NS NSpercentage of patients with fractures were asymptomatic
in the IBD group (46.3%) and control group (71.4%).
In our study, patients with IBD presented a risk of
fracture 4.03 times higher than that of controls (OR,
4.03; 95% CI, 1.652–9.847; p< 0.002). In the multivariate
analysis, the only observed predictive factor related to
fracture was IBD.
BMD
Bone mass in the lumbar spine was significantly lower in
patients with IBD than in controls (0.940 ± 0.15 vs.
1.008 ± 0.16 gHA/cm2; p= 0.01) and the femur
(0.836 ± 0.17 vs. 0.718 ± 0.13 gHA/cm2; p= 0.04). Differ-
ences between patients with CD and those with UC were
not found.
To avoid the effects of menopause, only premenopau-
sal women were evaluated. Bone mass was also found to
be significantly lower in the IBD group in the lumbar
spine (0.937 ± 0.13 vs. 1.028 ± 0.13 gHA/cm2; p= 0.02).
Differences in the femur were not observed.
A total of 42.05% of patients with IBD had normal bone
mass, 43.92% had osteopenia, and 14.01% had osteoporosis.
In the control group, 65.3% had normal bone mass,
34.7% had osteopenia, and 0% had osteoporosis. After
applying the chi-square test, statistically significant
differences (p= 0.01) were found in the distribution of
both groups.
Despite a lower bone mass with frequent corticoster-
oid use, statistically significant differences were not
found between patients treated or not treated with corti-
costeroids or between patients on corticosteroids for
more or less than a year, continuously or sporadically.
Therefore, these parameters were not correlated. Cor-
ticosteroid use was very similar between patients with
CD and those with UC.
Biochemical parameters and bone remodeling
In patients with IBD, PTH, calcium, phosphorus, and
alkaline phosphatase were within their respective normal
ranges. Differences among these parameters were not
found when classifying them according to type of disease
(CD or UC) or when related to corticoid use.
In the IBD group, 55.14% of patients showed serum
vitamin D levels of <30 ng/ml, 25 (23.3%) patients had
levels of <20 ng/ml, and 5 had levels of <12 ng/ml.
However, vitamin D levels were similar to those in
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between the populations (27.2 ± 11.4 vs. 24.03 ± 19.1;
p= 0.06, NS). Differences in vitamin D levels between
patients with or without fractures were not found.
Higher PTH serum levels were seen in patients
with lactose intolerance compared with those without
(42.03 ± 16.0 vs. 32.01 ± 17.6 pg/ml; p= 0.04).
CRP was identical in patients with or without frac-
tures. However, CRP levels were higher in patients with
IBD and bone mass levels were<−1 SD compared with
patients with BMD>−1 SD (10.0 ± 11.7 vs. 5.3 ± 3.8;
p= 0.03).
Serum osteocalcin was not different between patients
with IBD and healthy subjects, regardless of whether or
not they suffered fractures (3.36± 2.7 vs. 3.51 ± 2.4 ng/ml).
OPG and RANKL levels, although slightly higher in
osteoporotic patients with IBD, were not related to bone
mass, showing similar values in patients with osteopenia,
osteoporosis, and normal bone mass as well as in
patients with or without a history of fractures. A correl-
ation was only found between OPG and PTH serum
levels in fracture patients with IBD (r = 0.520; p= 0.02).
This association was not found in IBD patients without
fractures.
In the multivariate analysis, none of the measured
parameters was significantly predictive of fracture.
Discussion
Our data represent the first case–control study consecu-
tively compiled in a monographic unit during a 1-year
period, pairing controls and cases during the same
period of time. The study included patients with CD or
UC and involved assessment of BMD in all subjects,
measuring the prevalence of vertebral fractures with a
semiquantitative method and measuring biochemical
parameters related to bone metabolism.
In this study, the proportion of morphometric verte-
bral fractures in patients with IBD was significantly
higher (38.3%) than that in the control population
(13.7%). After analyzing other publications, the preva-
lence of osteoporotic fractures in patients with IBD var-
ies according to the different studies. Some authors
found a low prevalence (<14%) of vertebral fractures in
IBD [11,16], and others observed prevalences between
20% and 27% [3,9,10,17]. An adequate number of cases
was included in some studies, although only IBD popu-
lations were assessed without comparison with control
populations [3,11,16]. In other studies, the incidence of
fracture in patients with IBD was estimated based on
previous imaging studies without using a semiquantita-
tive method [18]. Other studies only included patients
with CD [8-11] or patients with low bone mass [8] with-
out comparing them with a control group of healthy
subjects studied in parallel. The prevalence of fracturesfound in the present study is higher than that in previ-
ous studies, and this could be explained by differences
between the sources used for data collection and differ-
ent objectives.
Differences in the prevalence of fractures between
patients with CD or UC have not been observed in line
with other authors [16]. Although many authors have
reported a higher prevalence of vertebral fractures in
patients with CD [8-11,17], there are also studies that
found a higher prevalence of fractures in patients with
UC [3].
Patients with IBD developed fractures at earlier
ages than did controls, consistent with other publica-
tions [8-11]. Only Bernstein et al. presented conflicting
data in patients <50 years of age with IBD [19].
The prevalence of vertebral fractures in our control
group was somewhat lower than that in large-population
studies in Europe, although in those studies, the
included patients were older; thus, it is expected that the
prevalence is higher [20-22].
The risk of fracture due to impact in our population
was higher than that in other studies (OR, 4.03%; 95%
CI, 1.652–9.847; p< 0.002). There are published studies
that found no differences in fracture risk among
patients with IBD and control populations [22,23].
Other authors have shown a low risk of fracture in
patients with IBD (RR, 1.2–1.5) [24-27]. A study of a
Canadian population showed an increased risk of frac-
ture in patients with UC (RR, 1.54 vs. 1.90) [18]. These
studies included a large number of patients and con-
trols, but the information comes from questionnaires
administered to patients without radiological confirm-
ation of the fracture. In our study, the higher risk is
explained by more exhaustive detection that was based
on radiological study.
Like the results of most authors, our results show a
significantly lower BMD in patients with IBD than in
controls in both the lumbar spine and femur
[3,9,17,28,29]. Differences in age or type of disease have
not been found, consistent with other studies [9,10].
Back pain, a clinical expression of vertebral fracture,
was not related to the presence of morphometric frac-
ture. Back pain was present in both groups (IBD and
healthy subjects) regardless of vertebral fracture. Silent
fractures were observed in 58.54% of patients with IBD
and in 35.0% of healthy subjects. Therefore, this clinical
manifestation is not considered useful for the diagnosis
of fracture [8].
Menopause has scarcely been studied in patients with
IBD in relation to osteoporotic fractures. In some stud-
ies, the appearance of fractures has been found to have
no relationship with menopause, which is similar to our
results [17-19]. In our study, premenopausal women had
a higher number of fractures than did postmenopausal
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pausal women with IBD, BMD already showed signifi-
cantly lower values, and 12 cases of fractures were
reported at an average age of 31.8 ± 5 years. Sex hor-
mone deficiency had no significant influence on either
vertebral fracture or low BMD in our patients, even as a
known risk factor for low bone mass.
Corticosteroid use remains a controversial issue in the
development of osteoporotic fractures in patients with
IBD. The need for corticosteroid treatment in many
cases of IBD has led to the hypothesis that this may
be an important factor involved in the appearance of
osteoporotic fractures. It is well known that corticoids
exert a deleterious effect on bone, and, although contra-
dictory results have been published in patients with IBD
[10,11,16,17], some authors propose corticosteroid use
as a predictive factor for osteoporotic fracture [11,17].
Others, in accordance with our results, do not consider
corticosteroid use to be causal of fracture in patients
with IBD [10,16,23].
Our results show a poor association between the inci-
dence of fracture and high doses of corticoids. Oddly,
in our study, those patients with higher doses and con-
tinuous corticosteroid use showed a lower number of
fractures than did those only treated during exacerbation
of the disease. The fact that most patients only used cor-
ticosteroids for short periods of time (exacerbation
phase) may explain the less pernicious effect on bone.
The biochemical and bone remodeling parameters
assessed in this study did not show significant differ-
ences in patients with IBD with or without fractures or
in healthy subjects.
However, a high proportion of patients with IBD
showed suboptimal levels of vitamin D (30 ng/ml) for
correct bone metabolism, although the levels were not
different from those in control subjects. These data have
been corroborated by other studies [30-33].
Differences in CRP were not found between patients
with or without fractures. The IBD group did not show
inflammatory activity at the time of inclusion in this
study, which justifies our results.
OPG serum levels were similar in patients with and
without fractures. Several authors [34,35] justify elevated
OPG levels in IBD patients with chronic bowel inflam-
matory activity. In our study, patients were not in an
acute phase of the disease, and osteoporotic fractures
did not occur at the time of inclusion. It is likely that
OPG levels were not different in the studied patients
when evaluating for the presence of fractures or lower
bone masses because of these differences.
Conclusions
The results of this study clearly show a higher preva-
lence of morphometric vertebral fractures in patientswith IBD compared with a healthy population with simi-
lar characteristics (OR, 4.03). A high percentage of these
fractures showed no clinical evidence. No association
with BMD, age, or corticosteroid use was found because
most fractures were observed in patients with normal
bone mass who were younger and had lower corticoster-
oid use than the population with fractures. From the
studied parameters, having the disease was the only fac-
tor proven to be predictive of fracture, supporting the
hypothesis of the important role played by proinflamma-
tory cytokines on vertebral fractures and low bone mass.
Lower bone mass and a high proportion of hypovita-
minosis D were observed in patients with IBD. Based on
these results, we consider the early detection of morpho-
metric fracture by X-ray to be very important regardless
of clinical symptoms and bone mass. Early preventive
and therapeutic measures are necessary to prevent the
occurrence of complications.
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